Document Page: First | Prev | Next | All | Image | This Release | Search
File: aaaac_02.txt
ROUTINE UNCLASSIFIED
PAGE 02 OF 02 RHDJGAA 1009 003888 16/0049Z
IN LOW MALARIA THREAT AREAS.
;B) CHLOROQUINE PHOSPHATE 500 MG (300 MG BASE) (ONE BY MOUTH EACH
WEEK STARTED TWO WEEKS PRIOR TO EXPOSURE, CONTINUED WEEKLY DURING
EXPOSURE, AND FOR SIX-TO-EIGHT WEEKS POST EXPOSURE). CHLOROQUINE
RESISTANT MALARIA IS HOT A PROBLEM IN POTENTIAL OPERATIONAL AREAS.
;3) IF NO MALARIA HAZARD AREA WAS ENTERED, INDIVIDUAL SHOULD RETURN
THEIR MALARIA PROPHYLAXIS TO THE ISSUER.
THE MEDICAL PERSONNEL IN THE AOR WILL BE THE AUTHORITY FOR
DESIGNATING A MALARIA HAZARD AREA AND MAY AUTHORIZE INDIVIDUALS TO
STOP (OR START) TAKING MALARIA PROPHYLAXIS.
(4) IF MALARIA HAZARD AREA WAS ENTERED, THEN NORMAL TERMINAL
PROPHYLAXIS OF EIGHT, WEEKLY DOSES OF 45 MG PRIMAQUINE SHOULD BE
ISSUED, IN ADDITION TO CONTINUING DOXYCYCLINE OR CHLOROQUINE,
FOLLOWING RETURN TO CONUS, (OVALE AND/OR VIVAX-MALARIA ARE PRESENT
IN AOR MALARIA AREAS),
2. MENINGOCOCCAL IMMUNIZATION (QUADRAVALENT, A/C/Y/w135, NSN 6505 01
2865312) SHOULD BE BROADENED TO INCLUDE ALL DEPLOYING PERSONNEL AS
SUPPLIES ALLOW, LACK OF MENINGOCOCCAL IMMUNIZATION WITHIN 5 YEARS
SHOULD NOT BE CONSIDERED A DETRIMENT TO DEPLOYMENT OF NONMEDICAL
PERSONNEL,
3. POINT OF CONTACT IS MAJ PHILIP A. LA KIER, NGB/SGP, DSN 858-8550.
BT
#1009
Document Page: First | Prev | Next | All | Image | This Release | Search